Dual Antiplatelet Therapy is NOT Appropriate for Nonobstructive CAD
For a patient with nonobstructive coronary artery disease (stenosis <50-70%), continuing both aspirin and clopidogrel is not appropriate, even without bleeding complications. This patient should be on aspirin monotherapy alone.
The Evidence Against DAPT in Nonobstructive CAD
The major guidelines 1, 2 clearly define when dual antiplatelet therapy (DAPT) is indicated:
- Acute coronary syndrome (ACS) with or without PCI - requires 12 months of DAPT
- Coronary stent implantation - requires minimum 12 months of DAPT
- Post-fibrinolytic therapy in STEMI - requires minimum 14 days, ideally 12 months
Nonobstructive CAD (stenosis 20-70% without intervention) is conspicuously absent from these indications 1, 2.
Direct Evidence in Nonobstructive CAD
A 2020 study specifically examined DAPT in nonobstructive CAD patients 3. The results were clear:
- Clopidogrel plus aspirin was NOT significantly more effective than aspirin alone in reducing myocardial infarction
- While there were some differences in cardiovascular event rates, the bleeding rate was significantly higher with DAPT
- This directly contradicts the use of DAPT in this population
The Bleeding Risk Reality
Even though your patient hasn't experienced bleeding yet, the FDA label data shows the increased risk is real 4:
- In the CURE trial, major bleeding occurred in 3.7% with DAPT vs 2.7% with aspirin alone
- Minor bleeding occurred in 5.1% vs 2.4%
- This represents an absolute increase of 1% major bleeding and 2.7% minor bleeding
The absence of bleeding so far doesn't justify continuing unnecessary dual therapy - it simply means the patient has been fortunate.
What This Patient Should Receive
Based on guidelines 1, 2 and recent evidence 5:
- Aspirin 75-100 mg daily as monotherapy for secondary prevention
- Consider clopidogrel 75 mg daily as an alternative if aspirin is not tolerated (recent meta-analyses 6, 7, 8, 5 suggest clopidogrel may actually be superior to aspirin for stable CAD)
- Discontinue the unnecessary second antiplatelet agent to reduce bleeding risk
Common Pitfall to Avoid
The critical error here is conflating "coronary artery disease" with "indication for DAPT." Having CAD (even with atherosclerosis) does not automatically warrant DAPT. The specific indications are:
- Active ACS (within 12 months)
- Recent stent placement (within 12 months minimum)
- Post-fibrinolytic therapy
Nonobstructive CAD is a chronic stable condition requiring single antiplatelet therapy only 1, 2.
The Risk-Benefit Analysis
For every 1000 patients treated with DAPT vs aspirin alone 9:
- Prevent: 13 MIs and 23 strokes
- Cause: 9 major bleeds and 33 minor bleeds
This trade-off is only acceptable when there's a clear indication (ACS, stent, etc.). In nonobstructive CAD without these indications, you're exposing the patient to bleeding risk without established benefit 3.
Bottom line: Stop the clopidogrel and continue aspirin monotherapy alone (or switch to clopidogrel monotherapy if preferred based on recent evidence). The patient is receiving unnecessary dual therapy that increases bleeding risk without proven benefit in nonobstructive CAD.